CAPR_OUT_1 [2025-04-17 18:13:41 -0400] 4385 Bytes | 1203 tokens | Cum: 1203 tkns (15.04% of 8k)
==========================================================================

We're scouting for winners today. Its 6:13 PM on Thu Apr 17, 2025 and I'm looking at Capricor Therapeutics (CAPR) up to $11.35 from $9.64

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Capricor Therapeutics (CAPR)
IPO: 2007-02-13 (18 Years Ago)
Market Cap: $432,782,014
Shares Outstanding: 45,680,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Here’s a list of headlines for Capricor Therapeutics:

Apr-01-25 09:00AM - Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
Mar-21-25 06:23PM - Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings
Mar-20-25 04:41PM - Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy?
Mar-20-25 04:41PM 10:21AM - Q4 2024 Capricor Therapeutics Inc Earnings Call
Mar-19-25 06:57PM - Capricor projects FDA priority review decision for deramiocel by August 2025
Mar-19-25 06:57PM 06:56PM - Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript
Mar-19-25 06:57PM 05:15PM - Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates
Mar-19-25 06:57PM 04:17PM - Capricor: Q4 Earnings Snapshot

Prior AI Reports for CAPR:
1. 2025-03-20 – Score: 65 – Target: 16.0000 – Highs: 14.7500 / 14.1600 / 13.32
capricor-therapeutics-shows-bullish-indicators-amid-high-insider-trading-activity

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-21T18:00:00Z - Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
B2 - 2024-10-17T10:00:00Z - Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
B3 - 2024-10-01T18:08:45Z - Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
B4 - 2024-07-02T12:01:01Z - Unveiling 6 Analyst Insights On Capricor Therapeutics
B5 - 2024-06-25T14:30:00Z - CORRECTION: Capricor Therapeutics
B6 - 2024-06-25T12:30:00Z - Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Capricor Therapeutics (CAPR).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CAPR_OUT_3 [2025-04-17 18:13:44 -0400] 862 Bytes | 217 tokens | Cum: 1422 tkns (17.77% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/general/biotech/24/10/41116169/capricor-therapeutics-is-up-over-100-could-rise-even-higherCapricor Therapeutics, a biotech company focused on developing treatments for Duchenne muscular dystrophy, has seen its stock surge over 100% after announcing plans to pursue full FDA approval for its primary drug deramiocel. The company believes it can receive full approval rather than accelerated approval based on positive clinical trial results.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_5 [2025-04-17 18:13:45 -0400] 976 Bytes | 289 tokens | Cum: 1713 tkns (21.41% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T14:30:55Z - uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr (NA...
A2 - 2025-04-17T08:52:05Z - 144,250 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Acquired by Kennedy Capital Management LLC...
A3 - 2025-04-16T07:28:10Z - Wellington Management Group LLP Invests $565,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)...
A4 - 2025-04-15T07:16:03Z - Vanguard Group Inc. Purchases 700,243 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)...
A5 - 2025-04-05T12:25:47Z - Cantor Fitzgerald Issues Positive Outlook for CAPR Earnings...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CAPR_OUT_7 [2025-04-17 18:13:46 -0400] 1181 Bytes | 337 tokens | Cum: 2052 tkns (25.65% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr (NASDAQ:CAR), Capricor Therapeutics (NASDAQ:CAPR)**Date: 2025-04-17Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/04/44866304/uniqure-hertz-global-eli-lilly-and-other-big-stocks-moving-higher-on-thursdayU.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday.

Shares of uniQure N.V. QURE rose sharply during Thursday's session after the company was granted FDA granted Breakthrough Therapy designation for AMT-130 for the treatment of Huntington's disease.

uniQure shares jumped 45.3% to $13.65 on Thursday.

Here are some other big stocks recording gains in today's session.

Structure Therapeutics Inc. GPCR gained 21.4% to $22.49. Hertz Global Holdings, Inc. HTZ rose 20.3% to $6.99 after Pershing Squar

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_9 [2025-04-17 18:13:48 -0400] 1181 Bytes | 326 tokens | Cum: 2380 tkns (29.75% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): e Capital Management disclosed a stake via a 13F. CNBC reported that Pershing Square's stake is 19.8%, through shares & swaps. Eli Lilly and Company LLY gained 15.3% to $847.08 after the company announced topline Phase 3 results from its ACHIEVE-1 trial, which showed orforglipron demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines. Capricor Therapeutics, Inc. CAPR rose 13.8% to $10.97. ClearPoint Neuro, Inc. CLPT gained 13% to $13.02. VersaBank VBNK rose 12% to $10.91. Evotec SE EVO jumped 10.7% to $3.6200 following FY24 financial results. Avis Budget Group, Inc. CAR gained 10.1% to $80.00. The move came as investors responded to news that billionaire investor Bill Ackman's Pershing Square Capital Management significantly increased its stake in Hertz Global Holdings Inc HTZ. Insteel Industries, Inc. IIIN gained 9.1% to $

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_11 [2025-04-17 18:13:50 -0400] 1181 Bytes | 329 tokens | Cum: 2711 tkns (33.89% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): 29.15 following second-quarter results. Fidelity National Information Services, Inc. FIS shares jumped 7% to $73.41. Fidelity National Information Services unveiled two strategic moves -- acquiring Global Payments' Issuer Solutions unit and selling its remaining stake in Worldpay. Dollar Tree, Inc. DLTR gained 4.4% to $76.40.

Now Read This:

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Photo via Shutterstock

CAPRCapricor Therapeutics Inc$10.498.87%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum83.00Growth-Quality-Value42.40Price TrendShortMediumLongOverviewCARAvis Budget Group Inc$80.2510.4%CLPTClearPoint Neuro Inc$12.9112.1%DLTRDollar Tree Inc$76.404.36%EVOEvotec SE$3.7013.2%FISFidelity National Information Services Inc$73.467.02%GPCRStructure Therapeutics Inc$2

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_13 [2025-04-17 18:13:51 -0400] 1125 Bytes | 298 tokens | Cum: 3011 tkns (37.64% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): 2.0719.1%HTZHertz Global Holdings Inc$7.3929.4%IIINInsteel Industries Inc$29.078.81%LLYEli Lilly and Co$841.4214.5%QUREuniQure NV$12.9437.8%VBNKVersaBank$10.8611.5%Got Questions? AskWhich biotech stocks could follow uniQure's rise?How can Hertz Global leverage its new investor?What impact will Eli Lilly's trial results have on competitors?Are there emerging biotech firms to watch after uniQure?Which investment strategies benefit from Hertz Global's stake increase?Could Capricor Therapeutics gain traction from market momentum?How might Fidelity National Information Services's moves affect fintech?Will Evotec SE's results attract more investors?Which healthcare ETFs could gain from Eli Lilly advancements?What other companies may experience shifts after uniQure's FDA news?Powered ByMarket News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_15 [2025-04-17 18:13:52 -0400] 1074 Bytes | 282 tokens | Cum: 3295 tkns (41.19% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-26 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion of our financial condition and results of operations should be read in conjunction with the audited CONS financial statements and the related audited co...

S2 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Capricor Therapeutics, Inc., a Delaware corporation (the Company), issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. A copy of the press rele...

S3 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Capricor Therapeutics, Inc., a Delaware corporation (the Company), issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. A copy of the press rele...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CAPR_OUT_17 [2025-04-17 18:13:53 -0400] 1181 Bytes | 249 tokens | Cum: 3546 tkns (44.32% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with the audited consolidated financial statements and the related audited consolidated notes to those statements included elsewhere in this Annual Report on Form 10-K. This discussion includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those set forth under Item 1A., Risk Factors or elsewhere in this annual report, our actual results may differ materially from those anticipated in these forward-looking statements.

Company Overview

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (D

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_19 [2025-04-17 18:13:53 -0400] 1181 Bytes | 244 tokens | Cum: 3792 tkns (47.40% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): MD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs.

Since our inception, we have devoted substantial resources to developing deramiocel and our other product candidates including our exosomes platform technology, developing our manufacturing processes, staffing our company and providing general and administrative support for these operations. We do not have any products approved for commercial sale. Our ability to eventually generate any product revenue sufficient to achieve profitability will depend on the successful development, approval and eventual commercialization of deramiocel for the treatment of DMD and our other product candidates. If successfully developed and approved, we intend and plan to commercialize deramiocel in the United States and Japan with our partner, Nippon Shinyaku Co

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_21 [2025-04-17 18:13:54 -0400] 1181 Bytes | 252 tokens | Cum: 4046 tkns (50.58% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ., Ltd., a Japanese corporation (Nippon Shinyaku). Capricor may enter into licensing agreements or strategic collaborations in other markets. If we generate product sales or enter into licensing agreements or strategic collaborations, or further distribution relationships, we expect that any revenue we generate will fluctuate from quarter-to-quarter and year-to-year as a result of the timing and amount of any product sales, milestone payments and other payments. If we fail to complete the development of our product candidates in a timely manner, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.

A summary description of our key product candidates, is as follows:

##TABLE_START Deramiocel for the treatment of DMD: Our core program is focused on the development and commercialization of a cell therapy techn

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_23 [2025-04-17 18:13:55 -0400] 1181 Bytes | 269 tokens | Cum: 4317 tkns (53.96% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ology (referred to herein as deramiocel) comprised of cardiosphere-derived cells (CDCs), which are a rare population of cardiac cells isolated from donated cells of healthy human hearts, for the treatment of DMD. Deramiocel is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, pro-angiogenic and anti-fibrotic actions of CDCs, which are mediated by secreted exosomes laden with bioactive cargo. Among the cargo elements known to be bioactive in CDC-exosomes are microRNAs. Collectively, these non-coding RNA species alter gene expression in macrophages and other target cells, dialing down generalized inflammation and stimulating tissue regeneration in DMD (and in a variety of other inflammatory diseases). This mechanism of action, consistent with the changes observed in clinical studies to date in circulating inflammatory biomarkers, contrasts with th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_25 [2025-04-17 18:13:56 -0400] 1181 Bytes | 259 tokens | Cum: 4578 tkns (57.23% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): at of exon-skipping oligonucleotides and gene therapy approaches, which aim to restore dystrophin expression. DMD pathophysiology is driven by the impaired production of functional dystrophin which normally functions as a structural protein in muscle. The reduction of functional dystrophin in muscle cells leads to significant cell damage and ultimately causes muscle cell death and fibrotic replacement. In DMD patients, heart muscle cells progressively die and are replaced with scar tissue. This cardiomyopathy eventually leads to heart failure, which is currently the leading cause of death among those with DMD. The annual cost of care for patients with DMD is very high and increases with disease progression. There is no currently approved treatment for DMD-cardiomyopathy, therefore, we believe that DMD represents a significant market opportunity for our product candidate, deramiocel. ##TA

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_27 [2025-04-17 18:13:58 -0400] 790 Bytes | 192 tokens | Cum: 4772 tkns (59.65% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): BLE_END

Biologics License Application (BLA): In the third quarter of 2024, we held a pre-BLA meeting with FDA where we discussed our rolling BLA submission schedule, potential label expansion, plans for commercial manufacturing as well as other topics. Subsequent to this meeting, we held several additional meetings with FDA and announced our intent to file a BLA based on existing cardiac data from our Phase 2 HOPE-2 and HOPE-2 OLE trials compared to patient-level natural history data. We completed...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CAPR_OUT_29 [2025-04-17 18:14:08 -0400] 7489 Bytes | 2093 tokens | Cum: 6867 tkns (85.84% of 8k)
==========================================================================

This is our set of metrics for Capricor Therapeutics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-------------------------+
| Volume: 1,508,350 | Perf Month: -7.94% | Option/Short: Yes / Yes | Sales Y/Y TTM: -11.55% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 1.27M | Perf Quarter: -16.67% | Short Float: 23.19% | ROE: -48.16% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 1.18 | Index: RUT | Short Ratio: 7.30 | ROI: -27.08% |
+-------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 52.50 | Market Cap: 513.87M | Short Interest: 9.30M | Sales Surprise: 215.98% |
+-------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 1.08 | Shs Outstand: 45.58M | Beta: 0.89 | EPS Surprise: 5.88% |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 7.81% | Shs Float: 40.12M | Sales Q/Q: -7.92% | P/E: - |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -10.32% | Inst Own: 38.85% | Sales past 5Y: 345.38% | Earnings: Mar 19 AMC |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -5.82% | Insider Own: 12.16% | Employees: 160 | |
+-------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 26.69% | Insider Trans: 0.00% | Debt/Eq: 0.03 | |
+-------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by Capricor Therapeutics officers or majority shareholders (if available).

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Marban Linda (CHIEF EXECUTIVE OFFICER) on 2025-03-03
- Common Stock: 25000 shares at $1.39 (D)
- Common Stock: 12500 shares at $0 (D) Footnote: Transferred to reporting person's ex-spouse pursuant to settlement in divorce proceeding.
- Stock Option (Right to Buy): 25000 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Litvack Frank (Unknown Title) on 2025-03-03
- Common Stock: 25000 shares at $1.39 (D)
- Common Stock: 2543 shares at $13.67 (D) Footnote: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on March 3, 2025 of $13.67. The options would otherwise expire on March 3, 2025, pursuant to their terms.
- Stock Option (Right to Buy): 25000 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by DUNBAR GEORGE W JR (Unknown Title) on 2025-03-03
- Common Stock: 750 shares at $1.39 (D)
- Stock Option (Right to Buy): 750 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Bergmann Anthony (CHIEF FINANCIAL OFFICER) on 2025-03-03
- Common Stock: 2500 shares at $1.39 (D)
- Stock Option (Right to Buy): 2500 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by COLLIER EARL M JR (Unknown Title) on 2025-02-27
- Common Stock: 750 shares at $1.39 (D)
- Stock Option (Right to Buy): 750 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 22270465.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -40467186.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 11.25
Average Volume: 1506134.04
30-Day High: 14.36
30-Day Low: 8.7

[Detailed Financials: TTM 2024]
- Total Assets: $170,481,086.00
- Total Liabilities: $25,018,750.00
- Total Equity: $145,462,336.00
- Current Assets: $163,385,267.00
- Current Liabilities: $21,026,176.00

[Income Statement: TTM 2024]
- Revenue: $22,270,465.00
- Net Income: $-40,467,186.00
- Gross Profit: N/A
- Operating Income: $-42,564,842.00
- Earnings Per Share (EPS): -1.15

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-3,407,861.00

[Detailed Financials: FY 2024]
- Total Assets: $170,481,086.00
- Total Liabilities: $25,018,750.00
- Total Equity: $145,462,336.00
- Current Assets: $163,385,267.00
- Current Liabilities: $21,026,176.00

[Income Statement: FY 2024]
- Revenue: $22,270,465.00
- Net Income: $-40,467,186.00
- Gross Profit: N/A
- Operating Income: $-42,564,842.00
- Earnings Per Share (EPS): -1.15

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-3,407,861.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Capricor Therapeutics (CAPR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Capricor Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because CAPR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CAPR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CAPR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CAPR to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Capricor Therapeutics.

11) ETHICAL_RATING[]
Rate Capricor Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Capricor Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CAPR_IN_31 [2025-04-17 18:14:08 -0400] 126 Bytes | 29 tokens | Cum: 7101 tkns (88.76% of 8k)
==========================================================================

====================================
[2025-04-17 18:14:08] # Analysis Completed
Elapsed Time: 28.55 seconds